CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Dasatinib 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01471106
NCT01471106Phase 2Completed
CompareCT.gov

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

M.D. Anderson Cancer Center·interventional·Posted Nov 11, 2011·Updated Jul 10, 2024

In Brief

A Phase 2 clinical trial evaluating Dasatinib for Breast Cancer. Completed, enrolled 26 participants across 2 sites.

Detailed Summary

The goal of this clinical research study is to learn if dasatinib can help prevent breast cancer from developing in the unaffected breast. Dasatinib is designed to decrease the activity of one or more proteins that are responsible for the uncontrolled growth of tumor cells. This is an investigational study. Dasatinib is FDA approved and commercially available for the treatment of leukemia. Its use in breast cancer patients in investigational. Up to 66 patients will take part in this multicenter study. Up to 60 will be enrolled at MD Anderson.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsSusan G. Komen Breast Cancer Foundation, Bristol-Myers Squibb

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2011
Enrollment StartJan 21, 2014
Primary CompletionJan 31, 2024
Study CompletionMay 30, 2024
TodayJul 2, 2026
Enrollment to primary: 10.0 yearsPosted 14.6 years ago

Interventions

Dasatinibdrug

Group 1: 40 mg by mouth once a day. Group 2: 80 mg by mouth once a day.